Is it safe to omit neoadjuvant chemo-radiation in mucinous rectal carcinoma?
Whilst accepting that the numbers are small, there was no statistical difference in outcome (DFS and OS) between patients receiving pre- or post-operative chemo-radiotherapy. In most MRC patients, tumor regression is not significant after nCXRT and there is considerable possibility of tumor progression during nCXRT treatment. So, nCXRT should be used with close follow-up in MRC for early detection of possible tumor progression. If the patient cannot tolerate nCXRT, it is possibly safe to do surgery followed by pCXRT. Prospective study is needed to study the value of nCXRT in MRC.
CAT appears to be a secretory product of the epithelial cells in the lateral lobes of the rat prostate. Further, CR from late-middle age opposed the age-associated loss of this intracellular enzyme activity.